Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

• Published in: Breast cancer research : BCR Vol. 23; no. 1; p. 16
• Main Authors: Altoe, Mirella L, Kalinsky, Kevin, Marone, Alessandro, Kim, Hyun K, Guo, Hua, Hibshoosh, Hanina, Tejada, Mariella, Crew, Katherine D, Accordino, Melissa K, Trivedi, Meghna S, Hershman, Dawn L, Hielscher, Andreas H
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 31.01.2021; BioMed Central; BMC
• Subjects: Adjuvant treatment; Algorithms; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - metabolism; Breast Neoplasms - therapy; Cancer; Cancer therapies; Carboplatin; Chemotherapy; Contralateral breast; Contrast agents; Diffuse optical tomography; Disease Management; Female; Hemoglobin; Humans; Image Processing, Computer-Assisted; Lymphatic system; Menopausal status; NAC; Neoadjuvant Therapy; Patients; pCR; Statistical analysis; Surgery; Tomography; Tomography, Optical - methods; Tomography, Optical - standards; Treatment Outcome; Tumor Burden; Womens health; Menopausal status; NAC; Breast cancer; Contralateral breast; Diffuse optical tomography; pCR
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-021-01396-w

The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing breast in patients administered neoadjuvant chemotherapy (NAC) for breast cancer are associated with pathologic complete response (pCR). In this retrospective evaluation of 105 patients with stage II-III breast cancer, oxy-hemoglobin (ctO Hb) from the contralateral non-tumor-bearing breast was collected and analyzed at different time points during NAC. The earliest monitoring imaging time point was after 2-3 weeks receiving taxane. Longitudinal data were analyzed using linear mixed-effects modeling to evaluate the contralateral breast ctO Hb changes across chemotherapy when corrected for pCR status, age, and BMI. Patients who achieved pCR to NAC had an overall decrease of 3.88 μM for ctO Hb (95% CI, 1.39 to 6.37 μM), p = .004, after 2-3 weeks. On the other hand, non-pCR subjects had a non-significant mean reduction of 0.14 μM (95% CI, - 1.30 to 1.58 μM), p > .05. Mixed-effect model results indicated a statistically significant negative relationship of ctO Hb levels with BMI and age. This study demonstrates that the contralateral normal breast tissue assessed by DOTBIS is modifiable after NAC, with changes associated with pCR after only 2-3 weeks of chemotherapy.